Pediatric Inflammatory Diseases: Immune Development and Shared Pathways Highlight Challenges for Targeted Therapy
Background: Understanding inflammatory diseases in a developing immune system
Designing targeted treatments for pediatric inflammatory diseases requires considering both disease-specific inflammatory pathways and the stage of immune development. This review in Translational Pediatrics discusses juvenile idiopathic arthritis (JIA), pediatric inflammatory bowel disease (IBD), asthma, Kawasaki disease, and multisystem inflammatory syndrome in children (MIS-C) from this perspective. It connects mechanisms described in existing literature with treatment approaches; it does not analyze a new patient cohort or directly compare treatment efficacy.
The authors focus on how childhood infections, environmental exposures, and genetic susceptibility interact with the developing immune system. During periods when immune cells differentiate and immune tolerance develops, the same stimulus may produce responses that differ from those in adults. Treatment decisions, they emphasize, should account not only for body weight but also for age, drug metabolism and excretion, and kidney function. Pediatric evidence is needed to support the application of dosing approaches derived from adult studies to children.
Key findings: Shared pathways and distinct disease targets
The review is organized around dysregulation of innate and adaptive immunity, cytokine signaling, inflammasomes, oxidative stress, and interactions between gut microbes and the immune system. It examines inflammatory pathways that overlap across diseases while also addressing disease-specific differences.
For example, the NLRP3 inflammasome is an intracellular protein complex that responds to infection or cellular stress. When activated, it engages caspase-1, which contributes to the maturation of the inflammatory signaling molecules interleukin-1 beta (IL-1β) and interleukin-18 (IL-18). The authors present dysregulation of this response as an important pathway for understanding pediatric inflammation. They also connect oxidative stress to the process by which excessive reactive oxygen species (ROS) damage cellular components and sustain inflammation.
For individual diseases, the review covers the interleukin-6 (IL-6) and Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathways in JIA. In asthma, it describes IL-4, IL-5, and IL-13 responses associated with T helper 2 (Th2) cells. For Kawasaki disease and MIS-C, it discusses systemic inflammation and vascular endothelial injury while noting that the two conditions arise in different contexts. The presence of shared pathways alone does not mean that the diseases will respond similarly to treatment.
The gut–immune relationship is another major theme. The authors link interactions among the intestinal epithelium, immune cells, and microbes, as well as microbe-produced short-chain fatty acids (SCFAs), to immune tolerance and intestinal homeostasis. They discuss the association between gut dysbiosis and inflammation and consider microbiome-based interventions as one direction for therapeutic research. Multi-omics approaches that examine genomics, proteomics, and metabolomics together are also presented as a way to investigate patient-specific molecular features and differences in treatment response.
Implications and outlook: Distinguishing therapeutic potential from the strength of evidence
Treatments reviewed include cytokine blockade, JAK inhibition, microbiome-based interventions, and gene editing. However, the level of pediatric clinical evidence differs across these approaches. Fecal microbiota transplantation (FMT) for pediatric IBD remains under study, and results have been inconsistent. The review also explicitly states that clinical evidence in children for gene editing and NLRP3 inhibitors is limited.
Assessment of targeted treatments should track not only reductions in inflammation but also infection, growth, and long-term immune function. Biomarkers and omics analyses are candidate approaches for predicting treatment response, but this review did not validate tools for assigning treatment to individual patients or companion diagnostics.
The limitations of interpretation are clear. The review did not conduct a quantitative systematic synthesis or meta-analysis and therefore cannot provide a pooled effect size. Differences in the designs, patient populations, and outcome measures of the included studies also limit direct comparisons. Caution is warranted when applying evidence weighted toward high-income countries to other healthcare settings. Disease- and age-specific clinical validation and long-term follow-up are needed to develop treatment strategies suited to pediatric immune development. Further discussion and limitations are available in the full review.
Pediatric inflammatory diseases, including juvenile idiopathic arthritis, pediatric inflammatory bowel disease, asthma, Kawasaki disease, and multisystem inflammatory syndrome in children, are an increasing global health concern. These conditions arise from dysregulated immune responses shaped by genetic susceptibility, environmental exposures, and the distinctive features of the developing pediatric immune system. This review presents a mechanism-centered overview of pediatric inflammation, emphasizing immune ontogeny, innate and adaptive immune dysregulation, cytokine signaling, inflammasome activation, oxidative stress, and the gut-immune axis. It also highlights emerging pathway-targeted therapies, including cytokine blockade, JAK inhibitors, microbiome-based interventions, and gene-editing strategies, with attention to their relevance for pediatric precision medicine. Early, mechanism-based intervention during critical developmental windows may improve long-term outcomes and reduce the lifetime burden of inflammatory disease. Overall, this review provides a concise, pediatric-focused perspective on how developmental immunology and targeted therapeutics can inform more precise and effective management of childhood inflammatory disorders.
In studies of targeted treatments for children, a reduction in inflammation in the joints or gut alone is insufficient to judge long-term benefit. For example, a JIA treatment study could track disease activity alongside growth, infections, and immune function, while examining differences in drug exposure by age, body weight, and kidney function. The review offers a framework for connecting these pediatric-specific measures with mechanistic research.
During development, it could inform follow-up studies testing whether cytokine or gut microbiome characteristics predict treatment response. However, the evidence is insufficient to turn the potential of microbiome modulation or gene editing directly into treatment recommendations. Clinical use requires separate validation of efficacy by disease and age, as well as long-term safety.